Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Iberdomide's EXCALIBER-RRMM Phase III trial positions CELMoD agents as the next-generation successor to lenalidomide in relapsed/refractory multiple myeloma.
Article | Rapport How AI-assisted code generation is reshaping firmware development workflows for embedded systems engineers — productivity, IP, and best practices.
Article | Rapport MET/VEGFR inhibitor zanzalintinib combined with atezolizumab targets metastatic colorectal cancer via dual pathway blockade. Explore the molecular rationale and IP landscape.
Article | Rapport Lanifibranor's NATiV3 Phase III readout is the most anticipated MASH event of 2026. Explore the pan-PPAR mechanism, histological endpoints, and competitive pipeline.
Article | Rapport How digital thread implementation transforms configuration management in aerospace MRO — covering model-based definition, part traceability, PLM integration, and regulatory compliance.
Article | Rapport How does amivantamab subcutaneous monthly dosing plus lazertinib stack up against osimertinib in first-line EGFR-mutant NSCLC? Clinical data, IP signals, and competitive analysis.
Article | Rapport How do engineers balance power density and thermal reliability in next-gen server PSU design? Explore key topologies, GaN/SiC devices, cooling strategies, and IP trends.
Article | Rapport Vertex Pharmaceuticals' suzetrigine targets NaV1.8 sodium channels for diabetic peripheral neuropathy. Explore the Phase III DPN program, patent landscape, and clinical implications.
Article | Rapport How AR-assisted assembly guidance reduces error rates in complex electronics manufacturing — technical mechanisms, innovation trends, and IP landscape analysis.
Article | Rapport ITM-11 (177Lu-edotreotide) NDA targets GEP-NET PRRT approval. Explore how it competes with Lutathera, key patent signals, and the second PRRT race.
Article | Rapport How engineers tackle electromagnetic interference shielding in wearable medical device design — materials, circuit techniques, regulatory standards, and patent strategies.
Article | Rapport How conformal cooling channel designs in injection mold tooling reduce warpage in complex polymer parts — engineering principles, thermal management, and IP landscape.
Article | Rapport Petosemtamab (MCLA-158) targets EGFR and LGR5 in HNSCC. Explore the Merus bispecific pipeline, Phase III design, and competitive landscape in head and neck cancer.
Article | Rapport How do engineers choose between ultrasonic and electromagnetic flow meters? Explore the key selection criteria, accuracy trade-offs, and application guidance.
Article | Rapport Gilead's lenacapavir twice-yearly injection redefines HIV PrEP. Explore PURPOSE trial results, patent landscape, and the long-acting prevention competitive landscape.